Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 69, Issue 10, 2014, Pages 1299-1305

  Cheng, Chin ^a,b   Lin, Ching Heng ^b   Tsai, Yi Wen ^c,d   Tsai, Chia Jui ^e   Chou, Po Han ^b,f   Lan, Tsuo Hung ^b,c,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^f UNIVERSITY OF TOKYO   (Japan)

Author keywords

Alzheimers; Cognition; Diabetes; Drug related; Medication; Risk factors

Indexed keywords

ANTIDIABETIC AGENT;

AGED; CHEMICALLY INDUCED; DEMENTIA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMAN; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

AGED; DEMENTIA; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84922222735     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glu073     Document Type: Article

References (25)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31-40. doi:10.1016/S0140-6736 (11) 60679-X
2. World Alzheimer Report 2010. Alzheimer's Disease International; 2010. http://www.alz.org/documents/national/world-alzheimer-report-2010.pdf. Assessed May 20, 2014.
3. Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia. 2005;48:2460-2469.
4. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5:64-74.
5. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology. 2010;75:1195-1202. doi:10.1212/WNL.0b013e3181f4d7f8
6. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-1262.
7. Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4:147-152.
8. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58:337-343. doi:10.2337/db08-1228
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med. 2002;346:393-403.
10. Norris SL, Zhang X, Avenell A, Gregg E, Brown TJ, Schmid CH, et al. Long-term non-pharmacologic weight loss interventions for adults with type 2 diabetes. Cochrane Database Syst Rev. 2005:CD004095. 2005;2: CD004095.
11. Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005;54:2404-2414.
12. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes. 2005;54:1566-1572.
13. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611-619.
14. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA. 2009;106:3907-3912. doi:10.1073/pnas.0807991106
15. Hsu CC, Wahlqvist ML, Lee MS, Tsai HN. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis. 2011;24:485-493. doi:10.3233/JAD-2011-101524
16. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
17. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180-1188.
18. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry. 2005;13:950-958.
19. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006;6:246-254.
20. Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, et al. A multi-center randomized proof-of-concept clinical trial applying [(1) F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010;22:1241-1256. doi:10.3233/JAD-2010-100939
21. Database NHIR. Introduction to the National Health Insurance Research Database (NHIRD), Taiwan. 2007. http://nhird.nhri.org.tw/date-01.html. Accessed May 20, 2014.
22. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PloS One. 2009;4:e4144. doi:10.1371/journal.pone.0004144
23. Halter JB. Diabetes mellitus in an aging population: the challenge ahead. J Gerontol A Biol Sci Med Sci. 2012;67:1297-1299. doi:10.1093/gerona/gls201
24. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Midand late-life diabetes in relation to the risk of dementia: a populationbased twin study. Diabetes. 2009;58:71-77. doi:10.2337/db08-0586
25. Le Couteur DG, McLachlan AJ, Quinn RJ, Simpson SJ, De Cabo R. Aging biology and novel targets for drug discovery. J Gerontol A Biol Sci Med Sci. 2012;67:168-174. doi:10.1093/gerona/glr095